The ICAM1 Knockout Jurkat Polyclonal Cells product offers a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the Jurkat human T-lymphocyte line, designed for loss-of-function studies of the intercellular adhesion molecule 1 (ICAM1). This polyclonal knockout model provides a genetically heterogeneous pool of edited cells, enabling robust investigation of ICAM1-dependent processes without clonal selection artifacts.
Jurkat cells, originally established from the peripheral blood of a patient with acute T-cell leukemia, serve as a widely utilized model for T-cell signaling, apoptosis, and activation. This suspension-adapted lymphocyte line recapitulates key aspects of T-cell receptor (TCR) signaling, making it an essential tool for dissecting molecular pathways governing immune cell function and leukemic transformation.
ICAM1 (CD54) is a transmembrane glycoprotein that mediates leukocyte adhesion and transendothelial migration through high-affinity binding to the integrins LFA-1 (ITGAL/ITGB2) and Mac-1 (ITGAM/ITGB2). Its expression is transcriptionally upregulated by pro-inflammatory cytokines including TNF-??, IL-1??, and IFN-?? via the NF-??B and AP-1 pathways. Upon ligand engagement, ICAM1 activates downstream signaling effectors such as Src family kinases and the MAPK cascade, driving actin cytoskeleton reorganization and facilitating cell motility. The pathway is further coordinated by adaptor proteins talin-1 and kindlin-3, which regulate integrin activation and linkage to the actin network. Importantly, ICAM1 also serves as a receptor for rhinovirus capsid proteins, contributing to viral entry.
In the Jurkat T-cell context, loss of ICAM1 disrupts adhesion-dependent signaling and transendothelial migration, directly impacting models of leukocyte extravasation and immune surveillance. This knockout cell population is particularly valuable for investigating how T cells interact with endothelial barriers during inflammation and how these interactions are altered in pathological states such as atherosclerosis and cancer metastasis. Moreover, abrogation of ICAM1 expression impairs LFA-1-mediated co-stimulatory signals, offering a platform to study TCR-proximal signaling and integrin inside-out activation.
Researchers can employ this knockout model in a variety of experimental setups, including static adhesion assays, transendothelial migration assays under shear flow conditions, and flow cytometric analysis of adhesion molecule expression. Additional applications involve studying tumor-immune crosstalk in co-culture systems, rhinovirus internalization pathways, and NF-??B-mediated inflammatory gene regulation. Complementary molecular readouts such as Western blotting and RT-qPCR allow quantitative assessment of pathway activation. For further information or technical support, please contact Ascent Research.
